the author Strategy: Immuno-Oncology Deal Trends, 2014–18
- Cancer research and treatment has evolved considerably over recent years, and one of the most promising modalities to emerge is immuno-oncology.
- Arguably one of the greatest breakthroughs in modern medicine, immuno-oncology essentially unlocks the breaks on the body's natural ability to attack and fight off cancer.
- Immuno-oncology therapeutics help to reprogram the immune system so that it recognizes and destroys cancer cells, which under normal circumstances may be able to evade an immune system attack.
- Pharmaceutical companies are pursuing several types of immuno-oncology products, including checkpoint inhibitors, tumor necrosis factor receptor agonists, adoptive T-cell therapies such as chimeric antigen receptor T-cell (CAR-T) technology, tumor-infiltrating lymphocytes, and vaccines.
- As of July 2019, there are 25 immuno-oncology therapies (including monotherapies and combinations with chemotherapies or other products, but excluding biosimilars) launched throughout the world for a wide range of solid and hematological tumors.
Table of Contents
Table of ContentsOverview
- Introduction
- Immuno-Oncology Deal Volume
- Deal Economics
- Disease Analysis
- Case Studies
- Bibliography
- Appendix
